Jill Thompson

TL;DR: It is shown, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus leads to infection of tumor cells subsequently resected as part of standard clinical care, both in high-grade glioma and in brain metastases, and increases cytotoxic T cell tumor infiltration relative to patients not treated with virus.

TL;DR: It is shown that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes.

TL;DR: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity.

TL;DR: The immune response is critical in mediating the efficacy of reovirus, and does not depend upon direct viral oncolysis or replication.

TL;DR: Reovirus infection of tumor cells reduces metastatic disease burden and primes antitumor immunity, and future clinical trials should be designed to explore both direct cytotoxic and immunotherapeutic effects of reovirus.